Literature DB >> 16110319

The concept of synthetic lethality in the context of anticancer therapy.

William G Kaelin1.   

Abstract

Two genes are synthetic lethal if mutation of either alone is compatible with viability but mutation of both leads to death. So, targeting a gene that is synthetic lethal to a cancer-relevant mutation should kill only cancer cells and spare normal cells. Synthetic lethality therefore provides a conceptual framework for the development of cancer-specific cytotoxic agents. This paradigm has not been exploited in the past because there were no robust methods for systematically identifying synthetic lethal genes. This is changing as a result of the increased availability of chemical and genetic tools for perturbing gene function in somatic cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16110319     DOI: 10.1038/nrc1691

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  530 in total

1.  Integrating molecular diagnostics into anticancer drug discovery.

Authors:  István Peták; Richárd Schwab; László Orfi; László Kopper; György Kéri
Journal:  Nat Rev Drug Discov       Date:  2010-06-07       Impact factor: 84.694

Review 2.  An intermittent approach for cancer chemoprevention.

Authors:  Xiangwei Wu; Scott M Lippman
Journal:  Nat Rev Cancer       Date:  2011-11-10       Impact factor: 60.716

3.  WT1: a weak spot in KRAS-induced transformation.

Authors:  Silvia Licciulli; Joseph L Kissil
Journal:  J Clin Invest       Date:  2010-10-25       Impact factor: 14.808

4.  Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.

Authors:  Anand G Patel; Silvana B De Lorenzo; Karen S Flatten; Guy G Poirier; Scott H Kaufmann
Journal:  Clin Cancer Res       Date:  2012-01-30       Impact factor: 12.531

Review 5.  An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy.

Authors:  R G Bristow; A Berlin; A Dal Pra
Journal:  Br J Radiol       Date:  2014-02-03       Impact factor: 3.039

6.  Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715.

Authors:  Roger B Slee; Brenda R Grimes; Ruchi Bansal; Jesse Gore; Corinne Blackburn; Lyndsey Brown; Rachel Gasaway; Jaesik Jeong; Jose Victorino; Keith L March; Riccardo Colombo; Brittney-Shea Herbert; Murray Korc
Journal:  Mol Cancer Ther       Date:  2013-11-26       Impact factor: 6.261

Review 7.  Tumor heterogeneity in the clinic: is it a real problem?

Authors:  Filip Janku
Journal:  Ther Adv Med Oncol       Date:  2014-03       Impact factor: 8.168

8.  Defects in homologous recombination repair genes are associated with good prognosis and clinical sensitivity to DNA-damaging agents in pancreatic cancer: A case report.

Authors:  Amir Sonnenblick; Aviad Zick; Myriam Maoz; Sherri Cohen; Luna Kadouri; Tamar Peretz; Ayala Hubert
Journal:  Mol Clin Oncol       Date:  2018-03-09

Review 9.  Revisiting p53 for cancer-specific chemo- and radiotherapy: ten years after.

Authors:  Jason M Beckta; Syed Farhan Ahmad; Hu Yang; Kristoffer Valerie
Journal:  Cell Cycle       Date:  2014-02-07       Impact factor: 4.534

Review 10.  Diffuse large B-cell lymphoma-treatment approaches in the molecular era.

Authors:  Mark Roschewski; Louis M Staudt; Wyndham H Wilson
Journal:  Nat Rev Clin Oncol       Date:  2013-11-12       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.